CNS Pharmaceuticals, Inc. short interest in 2020
In 2020, CNS Pharmaceuticals, Inc.'s disclosed short interest ran from 0.67% of shares outstanding on 15 Apr 2020 to 0.74% on 31 Dec 2020, a change of +0.07 percentage points. The year's high was 0.88% on 15 Jun 2020 and its low 0.39% on 15 Dec 2020, averaging 0.57% across 18 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 14.84 days on 15 May 2020. Full history: CNS Pharmaceuticals, Inc..
Cite this page
By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2020 in figures
- Start of year
- 0.67% (15 Apr 2020)
- End of year
- 0.74% (31 Dec 2020)
- Change
- +0.07 pp
- High
- 0.88% (15 Jun 2020)
- Low
- 0.39% (15 Dec 2020)
- Average
- 0.57%
- Highest days to cover
- 14.84 (15 May 2020)
- SEC filings marked
- 5
Every report in 2020
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Apr 2020 | 0.67% | 1.00 | 10-K filed, results (8-K) |
| 30 Apr 2020 | 0.47% | 1.00 | |
| 15 May 2020 | 0.49% | 14.84 | 10-Q filed |
| 29 May 2020 | 0.60% | 4.27 | |
| 15 Jun 2020 | 0.88% | 1.00 | |
| 30 Jun 2020 | 0.61% | 2.01 | |
| 15 Jul 2020 | 0.52% | 1.45 | |
| 31 Jul 2020 | 0.62% | 1.46 | |
| 14 Aug 2020 | 0.56% | 1.97 | 10-Q filed |
| 31 Aug 2020 | 0.74% | 1.00 | |
| 15 Sep 2020 | 0.55% | 1.07 | |
| 30 Sep 2020 | 0.52% | 2.57 | |
| 15 Oct 2020 | 0.46% | 2.62 | |
| 30 Oct 2020 | 0.46% | 5.14 | |
| 13 Nov 2020 | 0.48% | 1.38 | 10-Q filed |
| 30 Nov 2020 | 0.41% | 1.00 | |
| 15 Dec 2020 | 0.39% | 1.00 | |
| 31 Dec 2020 | 0.74% | 1.00 |
See also: CNS Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2020 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.